EUR-Lex · 17 Aug 2026 · 3 vistas
European Commission Approves GBL CVC Recordati Merger
Por FactBox Admin
Lede
The European Commission approved the merger between GBL, CVC and the Italian pharmaceutical company Recordati on 7 August 2026. The decision was published in the Official Journal of the European Union on 17 August 2026, under document number C/2026/4449.
Context
The decision falls under Council Regulation (EC) No 139/2004 (the EC Merger Regulation), specifically Article 6(1)(b), which allows the Commission to declare a concentration compatible with the internal market when it does not raise serious doubts about its compatibility. The case is registered as M.12479.
The Commission concluded that the notified concentration would not negatively affect the competitive landscape and declared it compatible with the internal market. The full text of the decision will be made public after any business secrets are removed.
Parties Involved
- GBL (Groupe Bruxelles Lambert)
- CVC (CVC Capital Partners)
- Recordati (pharmaceutical company)
Regulatory Details
- Case number: M.12479
- Legal basis: Council Regulation (EC) No 139/2004
- Decision date: 7 August 2026
- Publication: Official Journal of the European Union, C series, C/2026/4449, 17 August 2026
Access to Decision
The full decision is available in English on the Competition policy website of the European Commission and on EUR-Lex under document number 32026M12479.
Relevance
The approval of this merger is significant for the European pharmaceutical sector, as it consolidates the positions of GBL and CVC in the market through their acquisition of Recordati. The decision underscores the Commission’s role in overseeing major corporate transactions to ensure they remain compatible with the single market.
Source: Official Journal of the European Union, C/2026/4449, 17.8.2026 (official reference: CELEX:C_202604449).